MORRISTOWN, N.J., June 22, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in…Read More
Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for PreCirrhotic Fibrosis due to NASH
